Gland Pharma Ltd (NSE:GLAND) Share Price

Company Profile

Business description
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.
Contact
Plot No. 11 and 84, TSIIC Phase: IV
Pashamylaram (V), Patancheru (M)
Sangareddy District
HyderabadTG502307
IND
T: +91 8455699999
https://www.glandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
4,217

Recommended

Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.

Matt Wacher | 21 February 2025

We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.

Lochlan Halloway | 20 February 2025

Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.

Joseph Taylor | 20 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,570.90	30.80	-0.36%
CAC 40	8,154.51	31.93	0.39%
DAX 40	22,287.56	27.09	-0.12%
Dow JONES (US)	43,725.89	450.76	-1.02%
FTSE 100	8,659.37	3.60	-0.04%
HKSE	23,477.92	900.94	3.99%
NASDAQ	19,764.02	198.34	-0.99%
Nikkei 225	38,776.94	98.90	0.26%
NZX 50 Index	12,752.58	127.78	-0.99%
S&P 500	6,071.32	46.20	-0.76%
S&P/ASX 200	8,296.20	26.60	-0.32%
SSE Composite Index	3,379.11	28.33	0.85%